

Livio Trentin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5959483/livio-trentin-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

186
papers

5,430
citations

35
h-index

69
g-index

199
ext. papers

6,549
ext. citations

5
avg, IF

4.78
L-index

#	Paper	IF	Citations
186	A Case of Hemophagocytic Lymphohistiocytosis Triggered by Disseminated Tuberculosis and Hairy Cell Leukaemia after SARS-CoV2 Infection. <i>Applied Sciences (Switzerland)</i> , 2022 , 12, 564	2.6	
185	Necrotizing Follicular Lymphoma of the Inguinal Region with Sternbergoid Cells: ClinicalPathological Features of a Challenging Entity. <i>Applied Sciences (Switzerland)</i> , 2022 , 12, 1290	2.6	
184	Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three-factor model.. <i>American Journal of Hematology</i> , 2022 , 12, 1290	7.1	2
183	Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases.. <i>Current Oncology</i> , 2022 , 29, 1455-1460	2.8	
182	Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation.. <i>Frontiers in Oncology</i> , 2022 , 12, 835290	5.3	
181	Anaemia during venetoclax ramp-up phase: Do not forget unusual causes.. <i>International Journal of Laboratory Hematology</i> , 2022 , 12, 1290	2.5	0
180	Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.. <i>Frontiers in Oncology</i> , 2021 , 11, 801124	5.3	4
179	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021 , 35, 3444-3454	10.7	11
178	Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. <i>Blood</i> , 2021 , 138, 2641-2641	2.2	
177	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2021 , 5, 20210101	7.8	4
176	Protein Kinase CK1 β Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021 , 11, 733848	5.3	0
175	Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. <i>PLoS ONE</i> , 2021 , 16, e0247717	3.7	2
174	Incidental lymphomas in surgical pathology: diagnostic clues and clinical-pathological correlations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 1, 1-10	5.1	
173	Targeting Protein Kinases in Blood Cancer: Focusing on CK1 β and CK2. <i>International Journal of Molecular Sciences</i> , 2021 , 22, 1290	6.3	2
172	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021 , 11, 637186	5.3	4
171	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021 , 96, E306-E310	7.1	3
170	Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7501-7501	2.2	9

169	The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation. <i>Haematologica</i> , 2021 ,	6.6	8
168	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021 , 137, 3507-3517	2.2	12
167	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021 , 13,	6.6	5
166	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia</i> , 2021 , 35, 737-746	10.7	32
165	Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2021 , 39, 141-144	1.3	1
164	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021 , 137, 1365-1376	2.2	26
163	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021 , 106, 493-499	3.8	1
162	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021 , 96, E168-E171	7.1	5
161	Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. <i>European Journal of Haematology</i> , 2021 , 106, 439-449	3.8	7
160	Limbic Encephalitis with HU-Antibodies in T-cell Anaplastic Lymphoma. A Case Report. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 6548	2.6	
159	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021 , 39, 570-574	1.3	2
158	IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC. <i>Hematological Oncology</i> , 2021 , 39, 707-711	1.3	0
157	COMPLEX KARYOTYPE IN UNFIT PATIENTS WITH CLL TREATED WITH IBRUTINIB AND RITUXIMAB. THE GIMEMA LLC1114 PHASE 2 STUDY. <i>Blood</i> , 2021 ,	2.2	2
156	Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.. <i>American Journal of Hematology</i> , 2021 ,	7.1	3
155	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.. <i>Cancers</i> , 2021 , 14,	6.6	1
154	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020 , 136, 763-766	2.2	17
153	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020 , 34, 2354-2363	10.7	118
152	Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy. <i>Hematological Oncology</i> , 2020 , 38, 501-508	1.3	7

151	Frontline treatment with the combination obinutuzumab + chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020 , 95, 604-611	7.1	6
150	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study <i>Veritas Blood</i> , 2020 , 136, 47-49	2.2	
149	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020 , 136, 23-25	2.2	
148	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020 , 136, 30-31	2.2	
147	Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience. <i>Blood</i> , 2020 , 136, 32-33	2.2	1
146	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. <i>Blood</i> , 2020 , 136, 33-34	2.2	1
145	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020 , 136, 45-49	2.2	2
144	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , 2020 , 4, e395	0.3	2
143	New responsibilities for aged kinases in B-lymphomas. <i>Hematological Oncology</i> , 2020 , 38, 3-11	1.3	5
142	Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family. <i>Redox Biology</i> , 2020 , 37, 101705	11.3	10
141	Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia. <i>OncoTargets and Therapy</i> , 2020 , 13, 9679-9688	4.4	9
140	Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature. <i>Hematological Oncology</i> , 2020 , 38, 823-826	1.3	7
139	A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib. <i>Annals of Hematology</i> , 2020 , 99, 2715-2717	3	1
138	Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca ²⁺ -dependent death of cancer cells. <i>EMBO Reports</i> , 2020 , 21, e49117	6.5	28
137	Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020 , 190, 901-908	4.5	8
136	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020 , 9, 8468-8479	4.8	8
135	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. <i>Blood Cancer Journal</i> , 2020 , 10, 92	7	5
134	The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	11

133	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2019 , 121, 150-156	8.7	17
132	Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2019 , 104, 2053-2060	6.6	39
131	HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2019 , 145, 3089-3100	7.5	18
130	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 678-685.e4	3.2	12
129	BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. <i>British Journal of Haematology</i> , 2019 , 185, 193-197	4.5	16
128	Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma. <i>Cell Death Discovery</i> , 2019 , 5, 98	6.9	17
127	HIF-1 β /Wnt signaling-dependent control of gene transcription regulates neuronal differentiation of glioblastoma stem cells. <i>Theranostics</i> , 2019 , 9, 4860-4877	12.1	16
126	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019 , 37, 508-512	1.3	3
125	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019 , 11,	6.6	7
124	Circular RNA differential expression in blood cell populations and exploration of circRNA deregulation in pediatric acute lymphoblastic leukemia. <i>Scientific Reports</i> , 2019 , 9, 14670	4.9	42
123	Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals. <i>Cancers</i> , 2019 , 11,	6.6	19
122	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. <i>Cancers</i> , 2019 , 11,	6.6	21
121	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , 2019 , 133, 1205-1216	2.2	94
120	Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. <i>Human Pathology</i> , 2019 , 85, 251-259	3.7	3
119	Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL. <i>Leukemia</i> , 2019 , 33, 1148-1160	10.7	11
118	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018 , 103, 1209-1217	6.6	24
117	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. <i>British Journal of Haematology</i> , 2018 , 181, 229-233	4.5	25
116	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 20	7	11

115	Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-ALL). <i>Biochemical Pharmacology</i> , 2018 , 153, 230-241	6	17
114	Leukemia reconstitution is driven by cells in early cell cycle and low metabolic state. <i>Haematologica</i> , 2018 , 103, 1008-1017	6.6	3
113	Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2018 , 36, 366-369	1.3	5
112	Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine. <i>Annals of Hematology</i> , 2018 , 97, 2001-2003	3	
111	Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4 Infant ALL. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1705-1716	6.1	12
110	Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. <i>Hematological Oncology</i> , 2018 , 36, 801-803	1.3	3
109	Protective Role Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia: FOCUS on Subcutaneous Immunoglobulin Formulations. <i>Blood</i> , 2018 , 132, 4954-4954	2.2	1
108	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018 , 132, 3118-3118	2.2	4
107	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018 , 9, 23443-23450	3.3	8
106	CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. <i>Current Cancer Drug Targets</i> , 2018 , 18, 608-616	2.8	7
105	Three Different Jak2/Stat3-Related Pathways Favor the Survival of Chronic Lymphocytic Leukemia Neoplastic Clone. <i>Blood</i> , 2018 , 132, 4405-4405	2.2	
104	The Combination of Complex Karyotypes/Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018 , 132, 1844-1844	2.2	
103	Targeting Ras-Signalling Pathway to Strike Hsf1 and Induce Apoptosis in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018 , 132, 5533-5533	2.2	
102	Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2017 , 96, 159-161	3	9
101	Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1249-1254	8.9	20
100	Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo. <i>Cancer Cell</i> , 2017 , 31, 516-531.e10	24.3	92
99	Role of and the axis in regulating telomerase expression in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e253-e256	6.6	12
98	Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2017 , 178, 81-93	4.5	16

97	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2017 , 23, 5292-5301	12.9	20
96	Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. <i>Blood</i> , 2017 , 130, 643-654	2.2	43
95	Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. <i>European Journal of Cancer</i> , 2017 , 72, 103-111	7.5	22
94	Nerve ultrasound abnormalities mirror the course of varicella zoster virus sensory-motor radiculoplexopathy. <i>Muscle and Nerve</i> , 2017 , 55, E16-E18	3.4	2
93	Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. <i>Haematologica</i> , 2017 , 102, e140-e143	6.6	9
92	Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of gene refines prognosis in treatment-naïve chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e144-e147	6.6	4
91	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017 , 102, 1931-1935	6.6	7
90	Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2017 , 102, 1401-1412	6.6	17
89	Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2017 , 35, 925-928	1.3	15
88	Inactivation of CK1 β in multiple myeloma empowers drug cytotoxicity by affecting AKT and β -catenin survival signaling pathways. <i>Oncotarget</i> , 2017 , 8, 14604-14619	3.3	24
87	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2017 , 8, 91703-91710	3.3	12
86	Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. <i>Oncotarget</i> , 2017 , 8, 110727-110731	3.3	15
85	Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis. <i>Scientific Reports</i> , 2016 , 6, 34449	4.9	14
84	Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins. <i>Journal of Leukocyte Biology</i> , 2016 , 100, 1061-1070	6.5	9
83	LDH Levels Predict Progression-Free Survival in Treatment-Naïve Patients with Trisomy 12 Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 3211-3211	2.2	2
82	Evaluation of Integrated CLL Scoring System (ICSS) in 420 Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 5563-5563	2.2	1
81	Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells. <i>Oncotarget</i> , 2016 , 7, 57086-57098	3.3	13
80	HSP70-HSF1 Interplays Has a Role in the Pathogenesis of Chronic Lymphocytic Leukemia and Is a Druggable Target. <i>Blood</i> , 2016 , 128, 4368-4368	2.2	

79	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. <i>Blood</i> , 2016 , 127, 1007-16	2.2	110
78	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016 , 3, e467-e479	14.6	44
77	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4015-4022	2.2	49
76	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 612-20.e1-5	2	19
75	Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 592-8	2	2
74	Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2015 , 75, 4153-63	10.1	32
73	Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia. <i>Immunogenetics</i> , 2015 , 67, 61-6	3.2	19
72	Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. <i>Haematologica</i> , 2015 , 100, e515-8	6.6	37
71	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. <i>Blood</i> , 2015 , 125, 856-9	2.2	55
70	Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. <i>Blood</i> , 2015 , 125, 3747-55	2.2	33
69	Biophysical characterization and expression analysis of Kv1.3 potassium channel in primary human leukemic B cells. <i>Cellular Physiology and Biochemistry</i> , 2015 , 37, 965-78	3.9	22
68	Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model. <i>Oncotarget</i> , 2015 , 6, 1382-95	3.3	11
67	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014 , 89, 480-6	7.1	86
66	Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 123, 875-83	2.2	21
65	Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. <i>Haematologica</i> , 2014 , 99, 1826-33	6.6	17
64	Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2014 , 99, 1069-77	6.6	24
63	Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2014 , 99, 881-7	6.6	25
62	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. <i>Haematologica</i> , 2014 , 99, 1107-13	6.6	179

61	Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole. <i>British Journal of Haematology</i> , 2014 , 165, 659-72	4.5	17
60	Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 78	22.4	35
59	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013 , 88, 277-82	7.1	11
58	The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013 , 88, 289-93	7.1	15
57	Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. <i>American Journal of Hematology</i> , 2013 , 88, 955-60	7.1	14
56	Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. <i>Blood</i> , 2013 , 121, 3843-54, S1	2.2	61
55	Protein kinase CK2 inhibition down modulates the NF- κ B and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. <i>PLoS ONE</i> , 2013 , 8, e75280	3.7	59
54	R-Vemp Is a Safe and Effective Chemo-Immunotherapeutic Regimen In Elderly Unfit DLBCL Patients: Report From a Single Center-Experience. <i>Blood</i> , 2013 , 122, 3042-3042	2.2	
53	Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. <i>Blood</i> , 2012 , 119, 192-5	2.2	140
52	S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. <i>Blood</i> , 2012 , 120, 4391-9	2.2	38
51	HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen. <i>PLoS ONE</i> , 2012 , 7, e39902	3.7	25
50	Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. <i>Haematologica</i> , 2012 , 97, 56-63	6.6	43
49	SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection. <i>Experimental Biology and Medicine</i> , 2012 , 237, 793-802	3.7	16
48	KIR/HLA-I mismatching and risk of relapse in paediatric patients undergoing non-haploidentical allogeneic haematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2011 , 15, 198-204	1.8	9
47	BRAF mutations in hairy-cell leukemia. <i>New England Journal of Medicine</i> , 2011 , 364, 2305-15	59.2	791
46	Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. <i>PLoS ONE</i> , 2010 , 5, e13552	3.7	38
45	Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1919-27	2.2	64
44	Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes. <i>Haematologica</i> , 2010 , 95, 1722-9	6.6	18

43	Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. <i>BMC Cancer</i> , 2010 , 10, 526	4.8	30
42	Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. <i>European Journal of Haematology</i> , 2009 , 83, 406-19	3.8	40
41	Modulation of ER Stress/Unfolded Protein Response (UPR) Pathways in Multiple Myeloma Cells by Inhibition of Hsp90 and Serine-Threonine Kinase CK2.. <i>Blood</i> , 2009 , 114, 3840-3840	2.2	
40	Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 4665-74	2.2	50
39	Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. <i>Haematologica</i> , 2008 , 93, 697-705	6.6	30
38	Gene Expression Profile Analysis of Pediatric MDS Patients Correlates with FAB Classification and Has Prognostic Relevance. <i>Blood</i> , 2008 , 112, 2695-2695	2.2	
37	Effects of CK2 Inhibition on Multiple Signaling Pathways in Myeloma Cells. <i>Blood</i> , 2008 , 112, 5163-5163	2.2	
36	Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 68, 823-9	4	37
35	T-cell type lymphoproliferative disease of granular lymphocytes (LDGL) is equipped with a phenotypic pattern typical of effector cytotoxic cells. <i>Leukemia Research</i> , 2007 , 31, 371-7	2.7	10
34	Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. <i>British Journal of Haematology</i> , 2007 , 138, 594-602	4.5	35
33	New data on robustness of gene expression signatures in leukemia: comparison of three distinct total RNA preparation procedures. <i>BMC Genomics</i> , 2007 , 8, 188	4.5	12
32	Towards a new age in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2007 , 86, 159-72	3	28
31	Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. <i>Journal of Leukocyte Biology</i> , 2007 , 82, 946-55	6.5	35
30	Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3746-52	2.2	667
29	Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation. <i>Oncology Reports</i> , 2007 ,	3.5	2
28	Multiple myeloma cell survival relies on high activity of protein kinase CK2. <i>Blood</i> , 2006 , 108, 1698-707	2.2	113
27	CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis. <i>Respiratory Research</i> , 2005 , 6, 20	7.3	17
26	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. <i>Blood</i> , 2005 , 105, 931-9	2.2	35

25	Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). <i>Blood</i> , 2005 , 106, 3926-31	2.2	18
24	Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line. <i>British Journal of Haematology</i> , 2005 , 130, 878-89	4.5	10
23	Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 1290-8	10.2	70
22	Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. <i>Journal of Clinical Investigation</i> , 2005 , 115, 369-378	15.9	178
21	CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. <i>Clinical Cancer Research</i> , 2004 , 10, 964-71	12.9	49
20	T cells in the lung of patients with hypersensitivity pneumonitis accumulate in a clonal manner. <i>Journal of Leukocyte Biology</i> , 2004 , 75, 798-804	6.5	13
19	Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. <i>Blood</i> , 2004 , 104, 502-8	2.2	125
18	Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. <i>Blood</i> , 2003 , 102, 1797-805	2.2	87
17	The neutrophil-activating protein of Helicobacter pylori (HP-NAP) activates the MAPK pathway in human neutrophils. <i>European Journal of Immunology</i> , 2003 , 33, 840-9	6.1	38
16	Upregulation of CXCR1 by proliferating cells in patients with lymphoproliferative disease of granular lymphocytes. <i>British Journal of Haematology</i> , 2003 , 120, 765-73	4.5	7
15	High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. <i>Journal of Hepatology</i> , 2001 , 34, 723-9	13.4	15
14	Detection of identical T-cell clonotype expansions in both the donor and recipient after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 1999 , 106, 119-27	4.5	6
13	Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. <i>British Journal of Haematology</i> , 1999 , 106, 662-8	4.5	41
12	Interleukin-15: a novel cytokine with regulatory properties on normal and neoplastic B lymphocytes. <i>Leukemia and Lymphoma</i> , 1997 , 27, 35-42	1.9	35
11	Gamma delta T cell receptor subsets in the lung of patients with HIV-1 infection. <i>Cellular Immunology</i> , 1994 , 153, 194-205	4.4	23
10	CD8 alveolitis in sarcoidosis: incidence, phenotypic characteristics, and clinical features. <i>American Journal of Medicine</i> , 1993 , 95, 466-72	2.4	41
9	Spontaneous production of interleukin-6 by alveolar macrophages from human immunodeficiency virus type 1-infected patients. <i>Journal of Infectious Diseases</i> , 1992 , 166, 731-7	7	53
8	Expression of a functional p75 interleukin-2 receptor on lung lymphocytes from patients with human immunodeficiency virus type 1 (HIV-1) infection. <i>Journal of Clinical Immunology</i> , 1992 , 12, 371-80	5.7	6

7	Phenotypic and functional characterization of cytotoxic cells derived from endomyocardial biopsies in human cardiac allografts. <i>Cellular Immunology</i> , 1992 , 141, 332-41	4.4	9
6	Clonally expanded CD3+, CD4-, CD8- cells bearing the alpha/beta or the gamma/delta T-cell receptor in patients with the lymphoproliferative disease of granular lymphocytes. <i>Clinical Immunology and Immunopathology</i> , 1991 , 60, 371-83		9
5	Release of natural killer cytotoxic factor in patients with lymphoproliferative disease of granular lymphocytes. <i>Leukemia Research</i> , 1989 , 13, 315-22	2.7	5
4	Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. <i>Cancer</i> , 1989 , 64, 667-72	6.4	13
3	Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytes. <i>Cancer</i> , 1989 , 64, 2019-23	6.4	13
2	Lymphoproliferative disease of granular lymphocytes in a patient with concomitant hepatitis B virus infection of CD4 lymphocytes. <i>Journal of Clinical Immunology</i> , 1989 , 9, 401-8	5.7	6
1	Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: evaluation of cytotoxic events. <i>Leukemia Research</i> , 1987 , 11, 843-7	2.7	12